Rachel Lavelle
PharmD, BCCP
Rotations
Ambulatory Care: Advanced Heart Failure and Heart Transplant
Education
Undergraduate: Duke University
PharmD: The Ohio State University
Residency Training
PGY1: The Ohio State University Wexner Medical Center
PGY2 Cardiology: The Ohio State University Wexner Medical Center
Practice Interests
Cardiology, heart failure, hyperlipidemia, cardiac allograft vasculopathy, transitions of care
Professional Affiliation
American College of Clinical Pharmacy, member of the Cardiology PRN
American College of Cardiology, member of the Cardiovascular Team Section
American Society of Health System Pharmacists
Heart Failure Society of America
International Society of Heart and Lung Transplant (ISHLT)
Recent Publications
Okoroike H, Patel S, Simone P, Lavelle R, Szwak JA. Impact of inpatient initiation of sodium-glucose cotransporter-2 inhibitors on prescription rates in patients with heart failure with reduced ejection fraction. Am J Cardiol. 2023;186:150-155.
Brown AR, Lavelle RI, Gerlach AT. Discordance of renal drug dosing using estimated creatinine and measured urine creatinine clearance in hospitalized adults: a retrospective cohort study. Int J Crit Illn Inj Sci. 2020 Sep;10(Suppl 1):1-5.
Pickworth KK, Blais D, Cardiology Pharmacy Collaborative. COVID-19 pandemic: challenges and solutions from the cardiology pharmacist's perspective. J Am Coll Clin Pharm. 2020 Jul 17;10.1002/jac5.1307.
Lavelle RI, Brown AR, Gerlach AT. Correlation of measured and estimated creatinine clearance in hospitalized elderly patients: a retrospective cohort study. Hosp Pharm. Epub 2020 May.
Academic and/or National Presentations
Lavelle R, Loethen A, Pinney S et al. Impact of early belatacept use on 1-year CAV progression in heart transplant recipients. Poster presented at: International Society of Heart and Lung Transplantation, Denver, CO; April 21, 2023.
Murks C, Lavelle R, Besser SA, Nguyen A. Does anticholinergic effect of heart failure medication contribute to cognitive dysfunction? Poster presented at: International Society of Heart and Lung Transplantation [virtual]; April 29, 2022.
Okoroike HC, Patel SV, Simone P, Lavelle RI, Szwak JA. Impact of inpatient initiation of sodium-glucose cotransporter 2 inhibitors on guideline-directed medical therapy for heart failure with reduced ejection fraction patients. Poster presented at: American College of Cardiology's Annual Scientific Session & Expo; April 3, 2022.
SGLT-2 Inhibitors: Not Just for Diabetes Anymore. The University of Chicago Medicine Annual Courage and Innovation Symposium, Chicago, IL, March 2021
Intravenous Sodium Ferric Gluconate Complex And Iron Dextran Are Safe For Administration During Hospitalization For Heart Failure With Reduced Ejection Fraction. Heart Failure Society of America Annual Clinical Meeting [virtual], October 2020
Effect of Iron Dextran or Sodium Ferric Gluconate Complex Administration during Hospitalization for Heart Failure with Reduced Ejection Fraction. ACC.20/WCC Scientific Conference, April 2020
Effect of Iron Dextran or Sodium Ferric Gluconate Complex Administration during Hospitalization for Heart Failure with Reduced Ejection Fraction. Vizient University Health System Consortium Pharmacy Network Meeting, Las Vegas, NV, December 2019
Correlation of Measured & Estimated Creatinine Clearance in Hospitalized Elderly Patients. Vizient University Health System Consortium Pharmacy Network Meeting, Anaheim, CA, December 2018
Current Research
Clinical Impact of a Pharmacist-Led Medication Titration Clinic on Patients with Heart Failure with Reduced Ejection Fraction